A new test for tuberculosis (TB) could dramatically improve the speed and accuracy of diagnosis for one of the world’s deadliest diseases, enabling health care providers to report results to patients within minutes, according to a study published in the journal Angewandte Chemie. Jeffrey Cirillo, professor at the Texas A&M Health Science Center College of Medicine and investigators at Stanford University, have identified a new chemical compound to spot the bacteria that cause TB with a level of sensitivity that currently takes months to produce; and results of the first human clinical trial data are promising.
Findings show the test can determine that a patient has tuberculosis with 86 per cent sensitivity and 73 per cent specificity. Smear microscopy, the most widely used test in the world, has asignificantly lower ability to detect TB, ranging between 50 to 60 per cent sensitivity. Although preventable, TB claims three lives every minute, making it the second leading cause of mortality from an infectious disease in the world.
Spread through the air when an individual with active TB infection coughs or sneezes, reports show that if left untreated, a person with active TB infects an average of 10 to 15 people each year, leaving a need for reliable testing. Cirillo’s latest breakthrough perfects the technology behind the test. Using a fluorescent substrate, the device targets BlaC – an enzyme produced by the bacteria that cause TB – as an indicator of the bacteria’s presence. Until now, it has not been possible to target a specific TB enzyme for diagnosis. Once sputum samples are combined with the reactive substance, a batterypowered, portable tabletop device, the TB REaD, is then used to detect any fluorescence and deliver the diagnosis in as little as 10 minutes.
“It’s simple. Take a sputum sample, treat it with the solution and put it inside the reader,” Cirillo said. “A camera inside looks for a reaction between the sample and solution that produces light. No light, no infection.” Currently, there is no diagnostic tool comparable to this and while others exist, they take several months to produce the same level of sensitivity; and come with a high price tag. The target price tag on Cirillo’s test is less than $1000 for the reader and less than $5 per test. Additionally, the one-step test will require little technical expertise or resources, should take less than 30 minutes to carry out, and is easily transportable, making it an ideal candidate for field diagnosis in developing countries.
The device significantly undercuts current diagnostic methods, important, given the staggering statistic that if left untreated – a common scenario in countries lacking infrastructure or resources to efficiently screen and follow up with patients – a person with active TB has only a 50 per cent chance of survival, Cirillo notes. “Interrupting disease transmission will require early and accurate detection paired with appropriate treatment,” Cirillo said. “Our new, rapid point-of-care TB test dramatically reduces the current delays in diagnosis with incredible accuracy, accelerating appropriate treatment and reducing the death rate of the disease. We’re looking at a low-cost, easy-to-use test that has the potential to eradicate TB.” The test is currently in the later stages of clinical trials with plans to go to market in 18 months.
Findings show the test can determine that a patient has tuberculosis with 86 per cent sensitivity and 73 per cent specificity. Smear microscopy, the most widely used test in the world, has asignificantly lower ability to detect TB, ranging between 50 to 60 per cent sensitivity. Although preventable, TB claims three lives every minute, making it the second leading cause of mortality from an infectious disease in the world.
Spread through the air when an individual with active TB infection coughs or sneezes, reports show that if left untreated, a person with active TB infects an average of 10 to 15 people each year, leaving a need for reliable testing. Cirillo’s latest breakthrough perfects the technology behind the test. Using a fluorescent substrate, the device targets BlaC – an enzyme produced by the bacteria that cause TB – as an indicator of the bacteria’s presence. Until now, it has not been possible to target a specific TB enzyme for diagnosis. Once sputum samples are combined with the reactive substance, a batterypowered, portable tabletop device, the TB REaD, is then used to detect any fluorescence and deliver the diagnosis in as little as 10 minutes.
“It’s simple. Take a sputum sample, treat it with the solution and put it inside the reader,” Cirillo said. “A camera inside looks for a reaction between the sample and solution that produces light. No light, no infection.” Currently, there is no diagnostic tool comparable to this and while others exist, they take several months to produce the same level of sensitivity; and come with a high price tag. The target price tag on Cirillo’s test is less than $1000 for the reader and less than $5 per test. Additionally, the one-step test will require little technical expertise or resources, should take less than 30 minutes to carry out, and is easily transportable, making it an ideal candidate for field diagnosis in developing countries.
The device significantly undercuts current diagnostic methods, important, given the staggering statistic that if left untreated – a common scenario in countries lacking infrastructure or resources to efficiently screen and follow up with patients – a person with active TB has only a 50 per cent chance of survival, Cirillo notes. “Interrupting disease transmission will require early and accurate detection paired with appropriate treatment,” Cirillo said. “Our new, rapid point-of-care TB test dramatically reduces the current delays in diagnosis with incredible accuracy, accelerating appropriate treatment and reducing the death rate of the disease. We’re looking at a low-cost, easy-to-use test that has the potential to eradicate TB.” The test is currently in the later stages of clinical trials with plans to go to market in 18 months.